Global Next-Generation Biologics Market 2016-2020


#892950

124pages

Technavio

$ 2500

In Stock

About Next-generation Biologics

According to the section 351 of the Public Health Service Act of the US FDA, a biological product is defined as a virus, therapeutic serum, antitoxin, vaccine, toxin, blood, blood component or derivative, analogous product or allergenic product, applicable to the treatment, prevention, or cure of a condition or disease of human beings. Biologic therapeutics include virus, toxins, allergenic products, therapeutic serums, antitoxin, blood components or derivatives, vaccines, blood, proteins (except any chemically synthesized polypeptide), or analogous products, or arsphenamine or derivative of arsphenamine intended for the treatment, prevention, or cure of a disease or condition. The differences between the small molecules and biologics includes the molecular weight, structure, procedure of synthesis, and immunogenicity. Biologics usually have a higher molecular weight and a complex molecular structure. They are usually derived from living organisms, which is another important feature that differentiates it from small molecules. Biologics are also vulnerable to extreme temperatures and light.

Technavios analysts forecast the global next-generation biologics market to grow at a CAGR of 14.42% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global next-generation biologics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of next-generation biologics. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market during the forecast period.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Next-generation Biologics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
F. Hofmann-La Roche
Novo Nordisk
Sanofi
Takeda Pharmaceuticals

Other prominent vendors
Aastrom Biosciences
AbbVie
AbGenomics
Acologix
ADC Therapeutics
Adocia
Agensys
AlloCure
AlloSource
ALMAC Group
Alphatec Spine
Ambrx
Amorcyte
Argos Therapeutics
Astellas Pharma
AstraZeneca
Athersys
Avita Medical
Baxter
Bayer HealthCare
Bellicum Pharmaceuticals
BioCardia
Biocon
Biodel
BIOGENOMICS
BioLife Solutions
BioRestorative Therapies
BioTissue Technologies
Bluebird Bio
Boehringer Ingelheim
BrainStorm Cell Therapeutics
Calimmune
Capricor
CARBOGEN AMCIS
Cell Medica
Celldex Therapeutics
Celyad (Cardio3 BioSciences)
Cesca
CryoLife
CSL Behring
Cynata Therapeutics
Daiichi Sankyo
Dance Biopharm
Dendreon
Diasome Pharmaceuticals
DiscGenics
Endo Pharmaceuticals
Esperance Pharmaceuticals
Exsulin
Fate Therapeutics
Fibrocell Science
Formation Biologics
Forticell Bioscience
Fortress Biotech
Gamida Cell
GENEREX
Genmab
Geron
GlaxoSmithKline
Harvard Apparatus Regenerative Technology
Healthpoint
Histogen
Histogenics
Humacyte
Immunocellular Therapeutics
Immunogen
Integra LifeSciences
InVivo Therapeutics
ISTO Technologies
Juno Therapeutics
Juventas Therapeutics
Kairos Therapeutics
Kensey Nash
Kiadis Pharma
Kinetic Concept
Living Cell Technologies
MacroGenics
MannKind
MaxCyte
MedImmune
Medtronic
Mersana Therapeutics
Mesoblast
MiMedx
Nanofiber Solutions
Nanotope
Neuralstem
NewLink Genetics
NGM Biopharmaceuticals
Northwest Biotherapeutics
Novartis
NovaRx
Ocata Therapeutics
Opexa Therapeutics
Oramed Pharmaceuticals
Organovo
Orteq
Orthofix
Osiris Therapeutics
Osteotech
OXFORD BioTherapeutics
Pfizer
PhaseBio Pharmaceuticals
Pluristem Therapeutics
Prima BioMed
Q Therapeutics
ReproCELL
RhinoCyte
RTI Surgical
SanBio
Sangamo
Shire Regenerative Medicine
STEMCELL Technologies
Stemcentrx
Stratatech
Synthon Biopharmaceuticals
TEI Biosciences
Tengion
Thermalin Diabetes
TiGenix
Tissue Genesis
TissueGene
Tolerion
VentriNova
Vericel
VeroScience
ViaCyte
VistaGen Therapeutics
vTv Therapeutics
Wockhardt
XOMA
Zimmer Biomet
Zymeworks

Market driver
Advanced technological innovations
For a full, detailed list, view our report

Market challenge
Complexities in manufacturing of biologics
For a full, detailed list, view our report

Market trend
Development of gene and cell therapy-based products
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.




Table of Contents
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Market landscape
Market overview
Five forces analysis
PART 06: Market segmentation by application
Global regenerative medicine market
Global next-generation antibodies market
Global next-generation insulin products market
Global next-generation recombinant coagulation factors market
PART 07: Geographical segmentation
Next-generation biologics market in Americas
Next-generation biologics market in EMEA
Next-generation biologics market in APAC
PART 08: Market drivers
Increase in demand for ADCs
Advanced technological innovations
Reimbursement support for next-generation biologics
Special regulatory drug designations for biologics
PART 09: Impact of drivers
PART 10: Market challenges
Complexities in manufacturing of biologics
Complicated regulatory framework
Difficulties in patient recruitment for conducting clinical trials, high cost, and failure rate in clinical trials
Critical ethical challenges in clinical trial design
PART 11: Impact of drivers and challenges
PART 12: Market trends
Focus on regenerative medicines
Focus on oral insulin therapies
Development of gene and cell therapy-based products
Emergence of targeted and combination therapies
PART 13: Vendor landscape
Competitive scenario
Key news
Other prominent vendors
PART 14: Key vendor analysis
Biogen
F. Hoffmann-La Roche
Novo Nordisk
Sanofi4
Takeda Pharmaceuticals
PART 15: Appendix
List of abbreviations
PART 16: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Global next-generation biologics market
Exhibit 03: Overview of next-generation biologics market 2016-2020
Exhibit 04: Key strategies in global next-generation biologics market
Exhibit 05: Global next-generation biologics market snapshot: Developed and emerging markets 2015
Exhibit 06: Global next-generation biologics market 2015-2020 ($ billions)
Exhibit 07: Opportunities faced by biologics industry today
Exhibit 08: Five forces analysis
Exhibit 09: Global next-generation biologics market segmentation by therapies
Exhibit 10: Market share of next-generation biologics by application
Exhibit 11: Market overview of global regenerative medicine market
Exhibit 12: Sub-segmentation in regenerative medicine market
Exhibit 13: Global regenerative medicine market 2015-2020 ($ billions)
Exhibit 14: Funds from federal agencies for regenerative medicine research in 2014 ($ millions)
Exhibit 15: Cell therapy overview
Exhibit 16: Gene therapy products available in Europe
Exhibit 17: R&D in tissue scaffold
Exhibit 18: Opportunity analysis of global regenerative medicine market
Exhibit 19: Market overview of next-generation antibodies
Exhibit 20: Sub-segmentation in next-generation antibodies market
Exhibit 21: Global next-generation antibodies market 2015-2020 ($ billions)
Exhibit 22: Global next-generation antibodies market: Present and future scenario
Exhibit 23: Opportunity analysis of global next-generation antibodies market
Exhibit 24: Market overview of next-generation insulin products
Exhibit 25: Factors affecting global next-generation insulin products market
Exhibit 26: Global next-generation insulin products market 2015-2020 ($ millions)
Exhibit 27: Opportunity analysis of global next-generation insulin products market
Exhibit 28: Market overview of next-generation recombinant coagulation factors
Exhibit 29: Global next-generation recombinant coagulation factors market 2015-2020 ($ billions)
Exhibit 30: Opportunity analysis of global next-generation recombinant coagulation factors market
Exhibit 31: Impact of factors affecting the market 2015 and 2020
Exhibit 32: Global next-generation biologics market: Segmentation by geography (2015-2020)
Exhibit 33: Global next-generation biologics market segmentation by region: Market growth lifecycle analysis 2015
Exhibit 34: Overview of next-generation biologics market in Americas
Exhibit 35: Next-generation biologics market in Americas 2015-2020 ($ billions)
Exhibit 36: Stem cell research policies in Americas
Exhibit 37: Overview of next-generation biologics market in EMEA
Exhibit 38: Distribution of major cell therapy vendors in Europe 2011
Exhibit 39: Next-generation biologics market in EMEA 2015-2020 ($ billions)
Exhibit 40: Stem cell research policies in EMEA
Exhibit 41: Overview of next-generation biologics market in APAC
Exhibit 42: Global next-generation biologics market revenue by geography 2015-2020 ($ billions)
Exhibit 43: Key regenerative medicine market developments in Japan by global vendors 2015
Exhibit 44: Next-generation biologics market in APAC 2015-2020 ($ billions)
Exhibit 45: Stem cell research policies in APAC
Exhibit 46: ADC molecules currently under clinical trials
Exhibit 47: Advances in ADCs technology
Exhibit 48: Technologies used in next-generation biologics
Exhibit 49: Breakdown of CIRM funding in various stem cell research funding in 2014 ($ billions)
Exhibit 50: Active programs under CIRM in 2014
Exhibit 51: EC funding
Exhibit 52: Some of special regulatory designations approved by US FDA
Exhibit 53: Special regulatory designation approved by EU
Exhibit 54: Impact of drivers
Exhibit 55: Ethical issues that are faced by various institutes at different phases of cell therapy research
Exhibit 56: Impact of drivers and challenges
Exhibit 57: Impact of trends on global next-generation biologics market
Exhibit 58: Some of the regenerative medicines under development for the treatment of various musculoskeletal disorders
Exhibit 59: Planned clinical trials of iPS cell-based therapies
Exhibit 60: Regenerative medicines for IBS under development
Exhibit 61: Some of the mid- and late-stage pipeline products for regenerative medicine
Exhibit 62: Oral insulin pipeline portfolio
Exhibit 63: Gene therapies under development for hemophilia
Exhibit 64: Geographical presence of key vendors
Exhibit 65: Competitive scenario of global next-generation biologics market vendors 2015-2020
Exhibit 66: Biogen: Key highlights
Exhibit 67: Biogen: Strength assessment
Exhibit 68: Biogen: Strategy assessment
Exhibit 69: Biogen: Opportunity assessment
Exhibit 70: F. Hoffmann-La Roche: KADCYLA pipeline products
Exhibit 71: F. Hoffmann-La Roche: Key highlights
Exhibit 72: F. Hoffmann-La Roche: Strength assessment
Exhibit 73: F. Hoffmann-La Roche: Strategy assessment
Exhibit 74: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 75: Novo Nordisk: Highlights
Exhibit 76: Novo Nordisk: Strength assessment
Exhibit 77: Novo Nordisk: Strategy assessment
Exhibit 78: Novo Nordisk: Opportunity assessment
Exhibit 79: Sanofi: Highlights
Exhibit 80: Sanofi: Strength assessment
Exhibit 81: Sanofi: Strategy assessment
Exhibit 82: Sanofi: Opportunity assessment
Exhibit 83: Takeda Pharmaceuticals: Highlights
Exhibit 84: Takeda Pharmaceuticals: Strength assessment
Exhibit 85: Takeda Pharmaceuticals: Strategy assessment
Exhibit 86: Takeda Pharmaceuticals: Opportunity assessment